Abbisko Medicine Co., Ltd.

Abbisko Medicine Co., Ltd. is a legitimate registered non-Hong Kong company duly registered under Part 16 of the Companies Ordinance (Cap. 622) of Hong Kong on 2021-06-21 (operating for 5 years). According to the official register of the Hong Kong Companies Registry (CR), the entity holds an active statutory status of [Live / In Operation] (Statutory records last verified: November 2026).

The statutory primary identifiers for Abbisko Medicine Co., Ltd. are: 1. Business Registration Number (BRN / Unique Business Identifier UBI): [73101900] (effective from 27 December 2023, this 8-digit number issued under Cap. 310 serves as the unified cross-departmental corporate identifier); 2. Company Registration Number (CRN): [F0029523] (incorporation archive number issued under Cap. 622). Together, these dual keys uniquely lock the entity in international banking KYC and cross-border contracts.

Under the Companies Ordinance (Cap. 622) of Hong Kong, incorporated companies do not maintain a single 'legal representative' position; the Board of Directors (Section 643) exercises statutory management authority. Under the New Inspection Regime, public inspection displays directors' correspondence addresses and partially masked identification numbers. Complete current and historical directorships (Form ND2A), registered member shareholdings (Form NAR1 / Section 627), and Ultimate Beneficial Ownership (UBO / SCR under Part 12 Division 2A) are verified through official statutory filing retrieval.

Yes. According to the official statutory records of the Hong Kong Companies Registry, Abbisko Medicine Co., Ltd. has officially recorded 2 legal name change(s): [Abbisko Cayman Limited (effective 2021-06-21)], [Abbisko Cayman Limited (和譽開曼有限責任公司) (effective 2021-07-19)]. Pursuant to Sections 107 and 109 of the Companies Ordinance (Cap. 622), each name change was passed by special resolution (Form NNC2) and took statutory effect upon issuance of a Certificate of Change of Name by the Registrar of Companies; under Section 109(4), changing the company name does not affect any rights, obligations, or legal proceedings of the company.

Yes. Official filing registers of the Hong Kong Companies Registry confirm that Abbisko Medicine Co., Ltd. has statutory filings on official record (latest statutory filing indexed on 2026-10-15: CR Statutory Filing Document). Pursuant to Part 16 (Section 788) of the Companies Ordinance (Cap. 622), registered non-Hong Kong companies must deliver an Annual Return (Form NN3) to the Registrar of Companies within 42 days after each registration anniversary. Available verified original dossiers include: latest Annual Return of Non-Hong Kong Company (Form NN3 - detailing principal place of business in Hong Kong and authorised representatives), Application for Registration (Form NN1), Constitutive Documents, and Change of Secretary/Director/Authorised Representative notices (Form NN7 / NN8C), all carrying official ICRIS barcode verification.

According to multi-dimensional checks across Hong Kong statutory authorities: 1. Regulatory Licences: Officially licensed by Hong Kong statutory authorities, currently holding: Statutory Authority (Hkex) (Licence No. 02256); 2. Judicial Screening (Litigation & Winding-Up): cross-referenced with the Hong Kong Judiciary public writs database and Official Receiver's Office (ORO) registers; no public civil action writs (HCA/DCCJ) or compulsory winding-up petitions (HCCW under Cap. 32) were found on current index records.

The principal place of business in Hong Kong of Abbisko Medicine Co., Ltd. on official record is situated at: [40/F, Dominion Centre, 248 Queen's Road East, Wan Chai, Hong Kong]. Official registry dossiers also record 1 statutory registered office address change filing(s) (Form NR1). Pursuant to Part 16 (Section 791) of the Companies Ordinance (Cap. 622), all registered non-Hong Kong companies must maintain a principal place of business in Hong Kong and notify the Registrar within 15 days of any change (Form NN9) for the lawful service of statutory notices and court process.

Under Section 127 of the Companies Ordinance (Cap. 622), Hong Kong has abolished the mandatory use of a metallic common seal; Abbisko Medicine Co., Ltd. (CRN: F0029523 / 8-digit BRN: 73101900) may lawfully execute a commercial contract without a common seal by having the document signed on its behalf by its sole director (for a single-director company) or by two directors / one director and the company secretary. Because commercial rubber chops are not filed with the Hong Kong Government, counterparties must retrieve the latest Annual Return (Form NAR1) and director change notices (Form ND2A) from the Companies Registry to verify that the natural person signing is an active registered director.